Brief: Eagle Pharma And Enalare Therapeutics Announce Additional Award Worth Up To $50 Mln From BARDA To Advance Intramuscular Formulation Of ENA-001
27/09/2022 12:28
Sept 27 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS AND ENALARE THERAPEUTICS ANNOUNCE
ADDITIONAL AWARD WORTH UP TO $50 MILLION FROM BARDA TO ADVANCE
AN INTRAMUSCULAR (“IM”) FORMULATION OF ENA-001
* EAGLE PHARMACEUTICALS INC - ENALARE HAS SECURED A CONTRACT
FOR
UP TO $50.3 MILLION FROM BIOMEDICAL ADVANCED RESEARCH AND
DEVELOPMENT AUTHORITY
* EAGLE PHARMACEUTICALS INC - HAS OPTION TO ACQUIRE
REMAINING
ENALARE SHARES FOR AN AGGREGATE PURCHASE PRICE RANGING FROM
$100-$175 MILLION
Source text for Eikon: ID:nGNX73v5Y5
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq